Atomoxetine
- Atc Codes:N06BA09
- CAS Codes:82248-59-7#83015-26-3
- PHARMGKB ID:82248-59-7#83015-26-3
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Strattera; Belgium: Strattera; Cyprus: Strattera; Czech Republic: Strattera; Denmark: Strattera; Estonia: Strattera; Finland: Strattera; Germany: Strattera; Greece: Strattera; Hungary: Strattera; Ireland: Strattera; Italy: Strattera; Latvia: Strattera; Malta: Strattera; Netherlands: Strattera; Poland: Strattera; Portugal: Strattera; Romania: Strattera; Slovakia: Strattera; Slovenia: Strattera; Spain: Strattera; Sweden: Strattera; UK: Strattera.
North America
Canada: Strattera; USA: Strattera.
Latin America
Argentina: Recit, Strattera; Mexico: Strattera.
Drug combinations
Chemistry
Atomoxetine Hydrochloride: C~17~H~21~NO HCl. Mw: 291.82. (-)-N-Methyl-3-phenyl-3-(o-tolyloxy)propylamine hydrochloride. CAS-82248-59-7; CAS-83015-26-3 (tomoxetine)(2001).
Pharmacologic Category
Central Nervous System Agents, Miscellaneous; Selective Norepinephrine-Reuptake Inhibitor. (ATC-Code: N06BA09).
Mechanism of action
Selectively inhibits the reuptake of norepinephrine.
Therapeutic use
Treatment of attention-deficit hyperactivity disorder.
Pregnancy and lactiation implications
Use only if potential benefit to the mother outweighs possible risk to fetus. Use with caution during lactation.
Unlabeled use
Contraindications
Hypersensitivity to atomoxetine or any component of the formulation. Use with or within 14 days of MAO inhibitors. Narrow-angle glaucoma.
Warnings and precautions
Use with caution in pediatric patients (may be an increased risk of suicidal ideation). Aggressive behavior (particularly with the initiation of therapy). Allergic reactions (angioneurotic edema, urticaria, and rash) may occur. Risk of cardiovascular events in patients with serious cardiac problems. Rarely, severe hepatotoxicity may develop (use with caution in hepatic impairment and in poor metabolizers of CYP2D6-metabolized drugs). Priapism might occur (rarely). Does not worsen anxiety in existing anxiety disorders or tics related to Tourette’s disorder. Use with caution in hypertension and other cardiovascular conditions that might be exacerbated by increases in blood pressure or heart rate. Use caution in history of psychotic illness or bipolar disorder (may induce mixed/manic disorder or psychotic symptoms). Atomoxetine is not approved for major depressive disorder. Use cautiously in history of urinary retention or bladder outlet obstruction (may cause urinary retention/hesitancy).